论文部分内容阅读
脾切除有益于同种异体肾移植后的早期过程,据推测这是由于改善了对有骨髓毒性的硫唑嘌呤及其他免疫抑制药物的耐受能力.某些肿瘤患者作脾切除后可增强对化疗的耐受能力.β-地中海贫血或骨髓纤维化等伴巨脾的血液病患者亦可经脾切除而改善.但以上数类患者往往不能经受脾切除手术.此外,脾切除可带来细菌性脓毒症的危险.门静脉高压症患者脾切除可暂时降低门静脉压力而改善症状,但对此类患者脾切除是不恰当的,因为不仅以后无从作门体分流,而且脾切除仅有暂时的效果.Maddison曾报导脾动脉栓塞,但因脓肿形成等并发率高而未被广泛应用.此并发症似乎由完全性脾梗塞引起;部分梗塞而保留脾动脉顺向血流似乎是减少脾体积的相对安全且有效的方法.资料与方法:1976至1983年间,124例晚期肾脏
Splenectomy is beneficial for the early course of allograft renal allograft, presumably due to the improved tolerance of azathioprine and other immunosuppressive drugs with myelotoxicity Some patients with splenectomy may enhance the response to splenectomy Chemotherapy tolerance. Patients with splenomegaly, such as β-thalassemia or myelofibrosis, may also be treated with splenectomy, but these types of patients often can not undergo splenectomy. In addition, splenectomy can lead to bacterial Risk of sepsis. Splenectomy in patients with portal hypertension can temporarily reduce portal pressure and improve symptoms, but splenectomy is not appropriate for this type of patient because not only does it not allow subsequent shunting of the portal but the splenectomy is only temporary Effect .Maddison has reported splenic arterial embolization, but because of the high incidence of abscess formation and other complications have not been widely used.This complication appears to be caused by complete splenic infarction; partial infarction while retaining the splenic artery appears to be to reduce the volume of the splenic flow Relatively safe and effective method. Materials and Methods: From 1976 to 1983, 124 patients with advanced kidney disease